J
Jessica A. Walsh
Researcher at University of Utah
Publications - 100
Citations - 2255
Jessica A. Walsh is an academic researcher from University of Utah. The author has contributed to research in topics: Psoriatic arthritis & Medicine. The author has an hindex of 19, co-authored 72 publications receiving 1503 citations. Previous affiliations of Jessica A. Walsh include University of Pennsylvania & Veterans Health Administration.
Papers
More filters
Journal ArticleDOI
Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.
Jasvinder A. Singh,Gordon H. Guyatt,Alexis Ogdie,Dafna D. Gladman,Chad L. Deal,Atul Deodhar,Maureen Dubreuil,Jonathan Dunham,M. Elaine Husni,Sarah Kenny,Jennifer Kwan-Morley,Janice Lin,Paula Marchetta,Philip J. Mease,Joseph F. Merola,Julie Miner,Christopher T. Ritchlin,Bernadette C. Siaton,Benjamin J Smith,Abby S. Van Voorhees,Anna Helena Jonsson,Amit Aakash Shah,Nancy Sullivan,Marat Turgunbaev,Laura C. Coates,Alice B. Gottlieb,Marina Magrey,W. Benjamin Nowell,Ana Maria Orbai,Soumya M. Reddy,Jose U. Scher,Evan Siegel,Michael Siegel,Jessica A. Walsh,Amy S. Turner,James Reston +35 more
TL;DR: The 2018 ACR/NPF guideline as mentioned in this paper provides evidence-based guidelines for the pharmacologic and non-pharmacologic treatment of psoriatic arthritis (PsA) using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodology.
Journal ArticleDOI
Moral Injury: An Integrative Review
Brandon J. Griffin,Brandon J. Griffin,Natalie Purcell,Natalie Purcell,Kristine Burkman,Kristine Burkman,Brett T. Litz,Brett T. Litz,Craig J. Bryan,Martha Schmitz,Martha Schmitz,Claudia Villierme,Jessica A. Walsh,Jessica A. Walsh,Shira Maguen,Shira Maguen +15 more
TL;DR: Scientific research about moral injury is reviewed, summarizing lessons from the literature and offering recommendations for future research.
Journal ArticleDOI
2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
Jasvinder A. Singh,Gordon H. Guyatt,Alexis Ogdie,Dafna D. Gladman,Chad L. Deal,Atul Deodhar,Maureen Dubreuil,Jonathan Dunham,M. Elaine Husni,Sarah Kenny,Jennifer Kwan-Morley,Janice Lin,Paula Marchetta,Philip J. Mease,Joseph F. Merola,Julie Miner,Christopher T. Ritchlin,Bernadette C. Siaton,Benjamin J Smith,Abby S. Van Voorhees,Anna Helena Jonsson,Amit Aakash Shah,Nancy Sullivan,Marat Turgunbaev,Laura C. Coates,Alice B. Gottlieb,Marina Magrey,W. Benjamin Nowell,Ana Maria Orbai,Soumya M. Reddy,Jose U. Scher,Evan Siegel,Michael Siegel,Jessica A. Walsh,Amy S. Turner,James Reston +35 more
TL;DR: To develop an evidence‐based guideline for the pharmacologic and nonpharmacologic treatment of psoriatic arthritis (PsA), as a collaboration between the American College of Rheumatology and the National Psoriasis Foundation (NPF).
Journal ArticleDOI
The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)
Philip S. Helliwell,Philip S. Helliwell,Oliver FitzGerald,Jaap Fransen,Dafna D. Gladman,Gerald G Kreuger,Kristina Callis-Duffin,Neil McHugh,Philip J. Mease,Vibeke Strand,Robin Waxman,Valderílio Feijó Azevedo,Adriana Beltran Ostos,Sueli Carneiro,Alberto Cauli,Luis R Espinoza,John A. Flynn,Nada Hassan,Paul J. Healy,Eduardo Kerzberg,Yun Jong Lee,Ennio Lubrano,Antonio Marchesoni,Helena Marzo-Ortega,Giovanni Porru,Elvia G. Moreta,Peter Nash,Helena Raffayova,Roberto Ranza,Siba P. Raychaudhuri,Euthalia Roussou,Raphael Scarpa,Yeong Wook Song,Enrique R. Soriano,Paul P. Tak,Ilona Ujfalussy,Kurt de Vlam,Jessica A. Walsh +37 more
TL;DR: Two new composite measures to assess disease activity in PsA have been developed by multiple linear regression and empirically, utilising physician-defined cut-offs for disease activity, and area under the receiver operating curves (AUC) were generally smaller.
Journal ArticleDOI
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)
Maxime Dougados,James Cheng-Chung Wei,Robert Landewé,Joachim Sieper,Xenofon Baraliakos,Filip Van den Bosch,Walter P. Maksymowych,Joerg Ermann,Jessica A. Walsh,Tetsuya Tomita,Atul Deodhar,Désirée van der Heijde,Xiaoqi Li,Fangyi Zhao,Clinton C. Bertram,Gaia Gallo,Hilde Carlier,Lianne S. Gensler +17 more
TL;DR: Both ixekizumab regimens sustained improvements in disease activity, physical function, objective markers of inflammation, QoL, health status and overall function up to 52 weeks.